Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis
1University of Michigan, Ann Arbor, Michigan, USA.
Current Opinion in Rheumatology
|March 18, 2017
Summary
Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) have new treatments. While remission induction is successful, preventing relapses remains a challenge, prompting research into novel maintenance therapies.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare systemic diseases.
- Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are key AAV subtypes.
- Recent therapeutic advances have improved remission induction rates.
Purpose of the Study:
- To review recent therapeutic advances in ANCA-associated vasculitides.
- To address the challenge of preventing relapses in GPA and MPA.
- To evaluate newer strategies for maintaining remission and improving relapse-free survival.
Main Methods:
- Review of recent studies on AAV treatment.
- Analysis of therapeutic strategies for remission maintenance.
- Evaluation of prognostic indicators for relapse risk.
Main Results:
- Low-dose rituximab (RTX) is superior to azathioprine for remission maintenance.
- Late-stage relapses occur even after therapy withdrawal, suggesting longer treatment may be needed.
- Newer maintenance agents demonstrate benefits in maintaining remission and improving relapse-free survival.
Conclusions:
- Recent research offers improved approaches to prevent relapses in GPA and MPA.
- Novel maintenance therapies are effective in sustaining remission and reducing relapse rates.
- Further investigation into optimal treatment durations and prognostic indicators is warranted.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
01:14Myocarditis III: Medical Management
274
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
274
01:26Nephrotic Syndrome II : Assessment and Medical Management
285
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
285
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
616
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
616
01:24Nephrotic Syndrome III : Nursing Management
402
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
402
01:27Peripheral Artery Disease III: Interprofessional Care
457
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
457